Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
GAITHERSBURG, Md., Aug. 02, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its second quarter 2017 financial results after close of market on Tuesday, August 8, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and business progress.
Dial-in Information
U.S. Dial-In Number: (888) 883-4599
International Dial-In Number: (484) 653-6821
Conference ID: 61883667
Replay Dial-in Information
U.S. Dial-In Number: (855) 859-2056
International Dial-In Number: (404) 537-3406
Conference ID: 61883667
The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available after the conclusion of the call and will be archived on the company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor Contact: LHA Investor Relations Kim Sutton Golodetz 212-838-3777 [email protected] or Bruce Voss 310-691-7100 [email protected]
